Perspectives on lymphangiogenesis and angiogenesis in cancer

Journal of Surgical Oncology

Volumn 103, Issue 6, 2011, Pages 484-488

  Holopainen, Tanja ^c   Bry, Maija ^a   Alitalo, Kari ^a   Saaristo, Anne ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c University of Helsinki ^*

Author keywords

lymphedema; vascular biology; vascular endothelial growth factors

Indexed keywords

ADENOVIRUS VECTOR; AFLIBERCEPT; BEVACIZUMAB; CEDIRANIB; FIBROBLAST GROWTH FACTOR 2; NEUTRALIZING ANTIBODY; PLATELET DERIVED GROWTH FACTOR B; SCATTER FACTOR; SOMATOMEDIN C; SORAFENIB; SUNITINIB; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTICLE; BLOOD VESSEL PERMEABILITY; BREAST CARCINOMA; CANCER INVASION; CANCER SURVIVAL; CANCER SURVIVOR; CARCINOGENESIS; COLORECTAL CARCINOMA; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; LYMPHANGIOGENESIS; LYMPHATIC DRAINAGE; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TUMOR CELL; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; HUMANS; LYMPHANGIOGENESIS; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79953884077     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21808     Document Type: Article

References (86)

1. Risau W, Flamme I,: Vasculogenesis. Ann Rev Cell Dev Biol 1995; 11: 73-91. (Pubitemid 26019602)
2. Risau W,: Mechanisms of angiogenesis. Nature 1997; 386: 671-674. (Pubitemid 27193480)
3. Sabin FR,: On the origin of the lymphatic system from the veins and the development of the lymph hearts and thoracic duct in the pig. Amer J Anat 1902; 1: 367-391.
4. Wigle JT, Oliver G,: Prox1 function is required for the development of the murine lymphatic system. Cell 1999; 98: 769-778. (Pubitemid 29446894)
5. Karkkainen MJ, Haiko P, Sainio K, et al.: Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol 2004; 5: 74-80. (Pubitemid 38081471)
6. Francois M, Caprini A, Hosking B, et al.: Sox18 induces development of the lymphatic vasculature in mice. Nature 2008; 456: 643-647.
7. Kazenwadel J, Michael MZ, Harvey NL,: Prox1 expression is negatively regulated by miR-181 in endothelial cells. Blood 2010; 116: 2395-2401.
8. Pedrioli DM, Karpanen T, Dabouras V, et al.: miR-31 functions as a negative regulator of lymphatic vascular lineage-specific differentiation in vitro and vascular development in vivo. Mol Cell Biol 2010; 30: 3620-3634.
9. Abtahian F, Guerriero A, Sebzda E, et al.: Regulation of blood and lymphatic vascular separation by signaling proteins SLP-76 and Syk. Science 2003; 299: 247-251. (Pubitemid 36125210)
10. Bertozzi CC, Schmaier AA, Mericko P, et al.: Platelets regulate lymphatic vascular development through CLEC-2-SLP-76 signaling. Blood 2010; 661-670.
11. Uhrin P, Zaujec J, Breuss JM, et al.: Novel function for blood platelets and podoplanin in developmental separation of blood and lymphatic circulation. Blood 2010; 115: 3997-4005.
12. Liu W, Reinmuth N, Stoeltzing O, et al.: Antiangiogenic therapy targeting factors that enhance endothelial cell survival. Semin Oncol 2002; 29: 96-103 (review). (Pubitemid 34816071)
13. Bergers G, Song S, Meyer-Morse N, et al.: Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003; 111: 1287-1295. (Pubitemid 36554699)
14. Tammela T, Saaristo A, Holopainen T, et al.: Therapeutic differentiation and maturation of lymphatic vessels after lymph node dissection and transplantation. Nat Med 2007; 13: 1458-1466. (Pubitemid 350224251)
15. Tammela T, Alitalo K,: Lymphangiogenesis: Molecular mechanisms and future promise. Cell 2010; 140: 460-476.
16. Petrova TV, Karpanen T, Norrmen C, et al.: Defective valves and abnormal mural cell recruitment underlie lymphatic vascular failure in lymphedema distichiasis. Nat Med 2004; 10: 974-981. (Pubitemid 39273739)
17. Norrmén C, Ivanov KI, Cheng J, et al.: FOXC2 controls formation and maturation of lymphatic collecting vessels through cooperation with NFATc1. J Cell Biol 2009; 185: 439-457.
18. Mellor RH, Brice G, Stanton AW, et al.: Mutations in FOXC2 are strongly associated with primary valve failure in veins of the lower limb. Circulation 2007; 115: 1912-1920. (Pubitemid 46598905)
19. Srinivasan RS, Dillard ME, Lagutin OV, et al.: Lineage tracing demonstrates the venous origin of the mammalian lymphatic vasculature. Genes Dev 2007; 21: 2422-2432. (Pubitemid 47529372)
20. Religa P, Cao R, Bjorndahl M, et al.: Presence of bone marrow-derived circulating progenitor endothelial cells in the newly formed lymphatic vessels. Blood 2005; 106: 4184-4190. (Pubitemid 41775925)
21. Lohela M, Bry M, Tammela T, et al.: VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 2009; 21: 154-165.
22. Olsson AK, Dimberg A, Kreuger J, et al.: VEGF receptor signalling-in control of vascular function. Nat Rev Mol Cell Biol 2006; 7: 359-371.
23. Achen MG, McColl BK, Stacker SA,: Focus on lymphangiogenesis in tumor metastasis. Cancer Cell 2005; 7: 121-127. (Pubitemid 40248338)
24. Joukov V, Sorsa T, Kumar V, et al.: Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J 1997; 16: 3898-3911. (Pubitemid 27281006)
25. Stacker SA, Stenvers K, Caesar C, et al.: Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers. J Biol Chem 1999; 274: 32127-32136.
26. Karpanen T, Heckman CA, Keskitalo S, et al.: Functional interaction of VEGF-C and VEGF-D with neuropilin receptors. FASEB J 2006; 20: 1462-1472. (Pubitemid 44943854)
27. Wirzenius M, Tammela T, Uutela M, et al.: Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting. J Exp Med 2007; 204: 1431-1440. (Pubitemid 46919880)
28. Karpanen T, Bry M, Ollila HM, et al.: Overexpression of vascular endothelial growth factor-B in mouse heart alters cardiac lipid metabolism and induces myocardial hypertrophy. Circ Res 2008; 103: 1018-1026.
29. Schaper W,: The Renaissance of vascular endothelial growth factor, part B. Circ Res 2008; 103: 903-904.
30. Bry M, Kivelä R, Holopainen T, et al.: VEGF-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation. Circulation. 2010; 122: 1725-1733.
31. Caunt M, Mak J, Liang WC, et al.: Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell 2008; 13: 331-342. (Pubitemid 351446192)
32. Iozzo RV, San Antonio JD,: Heparan sulfate proteoglycans: Heavy hitters in the angiogenesis arena. J Clin Invest 2001; 108: 349-355. (Pubitemid 32730778)
33. Huang H, Bhat A, Woodnutt G, et al.: Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer 2010; 10: 575-585.
34. Shimoda H, Bernas MJ, Witte MH, et al.: Abnormal recruitment of periendothelial cells to lymphatic capillaries in digestive organs of angiopoietin-2-deficient mice. Cell Tissue Res 2007; 328: 329-337. (Pubitemid 46452201)
35. Tammela T, Saaristo A, Lohela M, et al.: Angiopoietin-1 promotes lymphatic sprouting and hyperplasia. Blood 2005; 105: 4642-4648. (Pubitemid 40807283)
36. Kim KE, Cho CH, Kim HZ, et al.: In vivo actions of angiopoietins on quiescent and remodeling blood and lymphatic vessels in mouse airways and skin. Arterioscler Thromb Vasc Biol 2007; 27: 564-570.
37. Wang HU, Chen ZF, Anderson DJ,: Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 1998; 93: 741-753. (Pubitemid 28257581)
38. Adams RH, Wilkinson GA, Weiss C, et al.: Roles of ephrinB ligands and EphB receptors in cardiovascular development: Demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes Dev 1999; 13: 295-306. (Pubitemid 29095801)
39. Wilkinson DG,: Multiple roles of EPH receptors and ephrins in neural development. Nat Rev Neurosci 2001; 2: 155-164. (Pubitemid 33673369)
40. Lawson ND, Scheer N, Pham VN, et al.: Notch signalling is required for arterial-venous differentiation during embryonic development. Development 2001; 128: 3675-3683. (Pubitemid 32998917)
41. Hanahan D, Folkman J,: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-364. (Pubitemid 26272076)
42. Folkman J,: Tumour angiogenesis: Therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
43. Hashizume H, Baluk P, Morikawa S, et al.: Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000; 156: 1363-1380. (Pubitemid 30660013)
44. Jain RK,: Antiangiogenic therapy for cancer: Current and emerging concepts. Oncology 2005; 19: 7-16 (review).
45. Ferrara N, Mass RD, Campa C, et al.: Targeting VEGF-A to treat cancer and age-related macular degeneration. Ann Rev Med 2007; 58: 491-504. (Pubitemid 46706529)
46. Kerbel R, Folkman J,: Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2: 727-739 (review). (Pubitemid 37328908)
47. Ebos JM, Lee CR, Kerbel RS,: Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res 2009; 15: 5020-5025 (review).
48. Lau SC, Rosa DD, Jayson G,: Technology evaluation: VEGF Trap (cancer). Regeneron/sanofi-aventis. Curr Opin Mol Ther 2005; 7: 493-501 (review). (Pubitemid 41489191)
49. Baka S, Clamp AR, Jayson GC,: A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis. Expert Opin Ther Targets 2006; 10: 867-876. (Pubitemid 44816749)
50. Youssoufian H, Hicklin DJ, Rowinsky EK,: Review: Monoclonal antibodies to the vascular endothelial growth factor receptor-2 in cancer therapy. Clin Cancer Res 2007; 13: 5544s-5548s. (Pubitemid 47510385)
51. Kerbel RS,: Issues regarding improving the impact of antiangiogenic drugs for the treatment of breast cancer. Breast 2009; 18: S41-S47.
52. Casanovas O, Hicklin DJ, Bergers G, et al.: Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005; 8: 299-309. (Pubitemid 41443415)
53. Batchelor TT, Sorensen AG, di Tomaso E, et al.: AZD2171, a pan-VEGF receptor tyrosine kinase inhibitos, normalizes tumor vasculature and alleviates edema in glioplastoma patients. Cancer Cell 2007; 11: 83-95. (Pubitemid 46075199)
54. Roberts N, Kloos B, Cassella M, et al.: Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res 2006; 66: 2650-2657.
55. Laakkonen P, Waltari M, Holopainen T, et al.: Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth. Cancer Res 2007; 67: 593-599. (Pubitemid 46192197)
56. Tammela T, Zarkada G, Wallgard E, et al.: Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 2008; 454: 656-660.
57. Carmeliet P, Tessier-Lavigne M,: Common mechanisms of nerve and blood vessel wiring. Nature 2005; 436: 193-200. (Pubitemid 41021263)
58. Pietras K, Pahler J, Bergers G, et al.: Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med 2008; 5: e19.
59. Sennino B, Falcõn BL, McCauley D, et al.: Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102. Cancer Res 2007; 67: 7358-7367. (Pubitemid 47206566)
60. Noguera-Troise I, Daly C, Papadopoulos NJ, et al.: Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 2006; 444: 1032-1037. (Pubitemid 46018516)
61. Ridgway J, Zhang G, Wu Y, et al.: Inhibition of D114 signalling inhibits tumor growth by deregulating angiogenesis. Nature 2006; 444: 1083-1087. (Pubitemid 46018529)
62. Crawford Y, Kasman I, Yu L, et al.: PDGF-C mediates the angiogenic and tumorigenic properties of fibroblast associated with tumors refractory to anti-VEGF treatment. Cancer Cell 2009; 15: 21-34.
63. Holash J, Maisonpierre PC, Compton D, et al.: Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 284: 1994-1998. (Pubitemid 29309448)
64. Rapisarda A, Melillo G,: Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies. Drug Resist Updat 2009; 12: 74-80.
65. Padera TP, Kadambi A, di Tomaso E, et al.: Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 2002; 296: 1883.
66. Sleeman JP, Thiele W,: Tumor metastasis and lymphatic vasculature. Int J Cancer 2009; 125: 2747-2756 (review).
67. Viley HE, Gonzales EB, Maki W, et al.: Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. J Natl Cancer Inst 2001; 93: 1638-1643. (Pubitemid 33094871)
68. Muller A, Homey B, Soto H, et al.: Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-56. (Pubitemid 32225831)
69. Mandriota SJ, Jussila L, Jeltsch M, et al.: Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J 2001; 20: 672-682. (Pubitemid 32167632)
70. Skobe M, Hawighorst T, Jackson DG, et al.: Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001; 7: 192-198. (Pubitemid 32148486)
71. Karpanen T, Egeblad M, Karkkainen MJ, et al.: Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res 2001; 61: 1786-1790. (Pubitemid 32691984)
72. Stacker SA, Caesar C, Baldwin ME, et al.: VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 2001; 7: 186-191. (Pubitemid 32148485)
73. Van den Eynden GG, Vandenberghe MK, van Dam PJ, et al.: Increased sentinel lymph node lymphangiogenesis is associated with nonsentinel axillary lymph node involvement in breast cancer patients with a positive sentinel node. Clin Cancer Res 2007; 13: 5391-5397. (Pubitemid 47510365)
74. Chen Z, Varney ML, Backora MW, et al.: Down-regulation of vascular endothelial cell growth factor-C expression using small interfering RNA vectors in mammary tumors inhibits tumor lymphangiogenesis and spontaneous metastasis and enhances survival. Cancer Res 2005; 65: 9004-9011. (Pubitemid 41377392)
75. Hirakawa S,: From tumor lymphangiogenesis to lymphvascular niche. Cancer Sci 2009; 100: 983-989 (review).
76. Lin J, Lalani AS, Harding TC, et al.: Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res 2005; 65: 6901-6909. (Pubitemid 41060729)
77. Shimizu K, Kubo H, Yamaguchi K, et al.: Suppression of VEGFR-3 signaling inhibits lymph node metastasis in gastric cancer. Cancer Sci 2004; 95: 328-333. (Pubitemid 38519473)
78. Albuquerque RJ, Hayashi T, Cho WG, et al.: Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. Nat Med 2009; 15: 1023-1030.
79. He XW, Liu T, Chen YX, et al.: Calcium carbonate nanoparticle delivering vascular endothelial growth factor-C siRNA effectively inhibits lymphangiogenesis and growth of gastric cancer in vivo. Cancer Gene Ther 2008; 15: 193-202. (Pubitemid 351240670)
80. He Y, Rajantie I, Pajusola K, et al.: Vascular endothelial growth factor receptor 3 mediated activation of lymphatic endothelium is crucial for tumor cell entry and spred via lymphatic vessels. Cancer Res 2005; 65: 4739-4746. (Pubitemid 40740810)
81. Karpanen T, Wirzenius M, Mäkinen T, et al.: Lymphangiogenic growth factor responsiveness is modulated by postnatal lymphatic vessel maturation. Am J Pathol 2006; 169: 708-718. (Pubitemid 44156326)
82. Norrmen C, Tammela T, Alitalo K,: Biological basis of therapeutic lymphangiogenesis. Circulation in press.
83. Becker C, Assouad J, Riquet M, et al.: Postmastectomy lymphedema: Long-term results following microsurgical lymph node transplantation. Ann Surg 2006; 243: 313-315. (Pubitemid 43327760)
84. Mebius RE, Streeter PR, Brevé J, et al.: The influence of afferent lymphatic vessel interruption on vascular addressing expression. J Cell Biol 1991; 115: 85-95. (Pubitemid 21909896)
85. Leppänen V-M, Jeltsch M, Anisimov A, et al.: Structural determinants of vascular endothelial growth factor-D -receptor binding and specificity. Blood in press.
86. Shojaei F, Zhong C, Wu X, Yu L, Ferrara N,. Trends Cell Biol. 2008; 18: 372-378.